Introduction
============

Lung cancer remains the leading cause of cancer death in the United States \[[@ref1]\]. The National Lung Screening Trial demonstrated that lung cancer screening with low-dose computed tomography (LDCT) has the potential to significantly reduce lung cancer mortality \[[@ref2]\]. On the basis of this and other evidence, the US Preventive Services Task Force (USPSTF) gave a B recommendation for LDCT screening \[[@ref3],[@ref4]\], the same strength of recommendation associated with mammography screening. However, real-world success in lung cancer screening will be conditional on identifying and screening those at highest risk for lung cancer while discouraging screening in those at low risk. Lung cancer screening presents a challenge, because it is the first population-wide screening modality with eligibility criteria based not only on age but also on a lifestyle behavior (at least 30 pack-years of tobacco use and smoking within the past 15 years). Identifying those at risk and helping them understand the benefits of screening and how to reduce their risk (e.g., tobacco cessation) is paramount for an effective implementation of population-wide lung cancer screening.

Implementing lung cancer screening in an environment where patients do not have the tools or information to understand disease risks and the harm-benefit balance of screening will most likely be counterproductive. In addition to providing information for individuals regarding lung cancer screening that allows them to weigh the potential harms of LDCT in accordance with the benefits, we also recognize that the decision to be screened is preference-sensitive. In light of this, there is a need to assist individuals with making informed decisions regarding lung cancer screening in which their personal values are also taken into account.

The USPSTF defines informed decision-making as "an individual's overall process of gathering relevant health information from both his or her clinician and from other clinical and nonclinical sources, with or without independent clarification of values" ( \[[@ref5]\], p. 59). In particular, a patient decision aid's functions are (1) to provide facts about an individual's condition and the options available and their characteristics, (2) to help individuals clarify values and personal preferences, and (3) to assist these individuals to discuss their values and preferences with health professionals \[[@ref6]\]. It is in this context that our goal is defined: to create a decision aid that improves the knowledge of LDCT screening, decreases decisional conflict, and improves concordance of screening preferences between the official recommendations and the individual (i.e., to assist individuals with informed decision-making about whether or not to screen). Concordance with official recommendations is important, because this will ensure that the resulting population of screened individuals is consistent with that for which lung cancer screening is deemed effective.

Evidence shows that decision aids can improve decision quality as a result of better knowledge of options and their associated harms and benefits; decrease decisional conflict; and reduce the overuse and increase the underuse of screening options \[[@ref7]-[@ref10]\]. In particular, Jimbo and colleagues \[[@ref9]\] focused on cancer screening and outlined recommendations for the evaluation of decision aids, the most important of which was to base the decision aid on a theoretical framework so that relevant outcomes are measured. The development of the decision aid in our study uses the Ottawa Decision Support Framework, a widely used theoretical framework that applies theories from psychology, social psychology, economics, and social support \[[@ref11]\].

Whereas numerous decision aids exist for prostate, colon, and breast cancers, there are only a handful of tools that fulfill the functions of a patient decision aid, either partially or fully, with regard to LDCT screening \[[@ref12]-[@ref16]\]. We are aware of only one that has formally evaluated measures of the effect of decision aids established in the theories of behavioral research in a peer-reviewed journal \[[@ref16]\]. However, this decision aid \[[@ref16]\] is in the format of a video that provides average risks and benefits of LDCT screening. We know that risk varies greatly among smokers \[[@ref17]\]; therefore, in our study, we propose to develop an alternative format: a Web-based, interactive decision aid that takes into account a more accurate depiction of an individual's personal lung cancer risk. The decision aid will comply with the qualifying and certification criteria set out in the International Patient Decision Aid Standards instrument (IPDASi) version 4.0 \[[@ref18]\]. The rationale for a Web-based tool is that the Web is increasingly becoming an important source of cancer information \[[@ref19]\]. Another advantage of the Web-based format is that the content of decision aids could easily be expanded and customized for different audiences. Studies have also confirmed the feasibility of using the Web to deliver the Web-based decision aids \[[@ref20]\].

Methods
=======

Prototype Development
---------------------

A prototype was developed based on the most recent clinical guidelines provided by the USPSTF \[[@ref5]\], the IPDASi version 4.0 checklist \[[@ref18]\], and recommendations in terms of risk communication \[[@ref21]-[@ref23]\]. The decision aid includes information on personalized lung cancer incidence risk calculated by using an established risk model \[[@ref24]\], risk factors of lung cancer reported in the literature, harms and benefits of LDCT screening, and an explicit values clarification exercise. We also used a currently existent print-based decision aid developed by the Veterans Affairs Healthcare System as a reference \[[@ref13],[@ref14]\].

The distinguishing factor of the Web-based version is that it allows individuals to compute their individualized lung cancer risk using an established risk model. Although all cancer screening is based on some risk factor identification, for the most common evidence-based cancer screening (e.g., colorectal, breast, and cervical cancer screening), risk factor identification involves little more than noting the relevant age and sex data. Lung cancer screening differs in very important ways in that proper application of current recommendations involves measuring risk by also identifying the individual's cumulative tobacco exposure measured in pack-years and the timing of tobacco use. Whereas smoking history accurately identifies risk on a population basis, it is less useful for individuals because there is such great variability of lung cancer risk, even among smokers with similar exposure. Current models that more accurately quantify individual lung cancer risk incorporate up to 10 clinical and demographic variables that provide a more accurate, though complex, determination of risk. This requires sophisticated lung cancer risk prediction models \[[@ref24]\].

In addition to accurately characterizing individual lung cancer risk, there is evidence that individuals may prefer to have such tailored information, which, in turn, may affect health-care-seeking decisions \[[@ref10],[@ref25]\]. To this end, personalized risk in absolute terms (as a percentage) and individualized benefits in the form of icon arrays are generated by the decision aid. We also provide average harms as an estimation of individual harms (see [Multimedia Appendix 1](#app1){ref-type="app"} for the current iteration of the results page).

We believe that putting LDCT screening in context with other common screening recommendations in terms of reduction of disease-specific mortality (i.e., reduction of breast cancer death by screening with mammography) will allow the individual to gauge how LDCT screening compares to other widely accepted screening practices. This has not been done with the available decision aids for LDCT lung cancer screening \[[@ref13],[@ref14],[@ref16]\].

Participants
------------

Our target population comprised of potential users of LDCT screening. The specific inclusion criteria are given in [Textbox 1](#box1){ref-type="boxed-text"}.

These criteria applied to all 3 phases of the study detailed below: Phase I alpha testing focus groups, Phase IIa beta testing before-after survey, and Phase IIb beta testing postsurvey focus groups.

###### Inclusion criteria.

-   Current and former smokers

-   Aged 45-80 years

-   No history of lung cancer

-   No previous chest computed tomographic scan in the past year

Recruitment Procedure
---------------------

A combination of passive and active recruitment was done to form 2 convenience samples of participants: 10 for alpha testing and 60 for beta testing. An advertisement was placed on the University of Michigan's (UM's) online portal for volunteers of clinical studies \[[@ref26]\], along with flyers at all of the clinics in the University of Michigan Health System (UMHS) and district libraries in Ann Arbor. Active recruitment involved in-person recruitment at a pulmonary clinic and general internal medicine clinic in the UMHS. Also, a list of participants and their contact details was generated by the Honest Broker Office of UM Medical School from medical records who fulfilled the inclusion criteria as listed above. The project coordinator verified the eligibility of all potential participants over the phone.

Phase 1: Alpha Testing
----------------------

### Overview

We solicited feedback from public health and health risk communication experts with regard to the content and wording and how risk is expressed in the prototype. After incorporating their suggestions, we conducted focus groups with potential users of LDCT screening to test the usability of the prototype as part of the decision tool's iterative development process. Specifically, we pretested our tool for comprehension of the content, as well as the acceptability of the design, layout, and messages conveyed. A total of 10 people participated in 1 of 2 focus groups. The eligible and willing participants were sent a Web link to work through the Web-based decision aid prototype via e-mail. All participants were asked to participate in the focus group within the week they reviewed the decision aid. Version 1 was the product of alpha testing.

### Data Collection

The focus group was conducted by a trained external facilitator and a study team member using an interview guide developed by study team members with expertise in qualitative research and lung cancer screening decision-making (see [Multimedia Appendix 2](#app2){ref-type="app"}). Focus groups were held at a venue at the UM School of Public Health. At the focus group, individuals were asked to complete a survey to document the demographic makeup of the focus group participants (see [Multimedia Appendix 3](#app3){ref-type="app"}). Thereafter, all participants accessed the decision aid again on an iPad individually to refresh their impression. After all participants in the focus group were done reviewing the tool, the external facilitator asked questions pertaining to the usability of the decision aid. All sessions were audiotaped, and field notes were taken. Ten minutes before the scheduled end of the focus group, the participants were asked to fill out an exit survey with 4 questions (see [Multimedia Appendix 4](#app4){ref-type="app"}).

### Analysis

Audio recordings were transcribed verbatim. Data analysis took place simultaneously with data collection, which, in turn, assisted in the iterative development of both the interview guide and decision aid. Using the transcriptions and field notes, a brief report was given by the study team member present at the focus groups to the rest of the study team. The study team then decided what changes to incorporate into the decision aid, forming version 1.

Phase IIa: Beta Testing: Self-Administered Electronic Survey
------------------------------------------------------------

### Overview

Following alpha testing, we conducted a pilot study of version 1 of our decision aid with 60 individuals using a quasi-experimental design: a before-after study. This study design is consistent with the development of a decision aid and is an accepted method to test the effectiveness of decision aid tools under "real-life" conditions \[[@ref16],[@ref27],[@ref28]\]. The before-after study will be followed by focus groups to gain further insight into the outcomes of interest and other spontaneous feedback about the tool in general.

### Data Collection

Following a successful screen for eligibility, a participant was invited to come to UM to complete a series of surveys administered on a computer by Qualtrics, an online survey tool. In particular, a participant began with the knowledge survey (see [Multimedia Appendix 5](#app5){ref-type="app"}). This was followed by the pretest demographic, lung cancer risk, and prior screening experiences survey (see [Multimedia Appendix 6](#app6){ref-type="app"}); risk perception of lung cancer and lung cancer screening (see [Multimedia Appendix 7](#app7){ref-type="app"}); and the decision conflict scale survey (see [Multimedia Appendix 8](#app8){ref-type="app"}). This formed the "before" survey, and the participant was automatically redirected to the website upon clicking "submit." The participant was instructed to explore the website for 10-15 minutes and on the final page, he or she would click on a link at the bottom that would redirect them to the "after" survey. The "after" survey comprised the knowledge, risk perception of lung cancer, and lung cancer screening; the values clarification questionnaire (see [Multimedia Appendix 9](#app9){ref-type="app"}); the decision conflict scale; and the acceptability survey (see [Multimedia Appendix 10](#app10){ref-type="app"}). The whole process lasted approximately 45 minutes.

### Analysis

The outcomes measured were adapted from the Ottawa Decision Support Framework: knowledge of the benefits and risks of lung cancer screening, acceptability \[[@ref29]\], decisional conflict \[[@ref30]\], and concordance between the USPSTF's recommendation and an individual's preference. Concordance is a binary variable defined as "Yes" = 1, where an individual prefers to get screened (or not to get screened) and is eligible (or ineligible) and "No" = 0 if an individual prefers not to get screened (or to get screened) but is eligible (or ineligible). We also measured a participant's risk perception as recommended by relevant literature \[[@ref9]\]. To compare before-after outcomes, we will use the Wilcoxon signed-rank test for continuous outcomes (knowledge and decisional conflict) and McNemar's test for binary outcomes (concordance and risk perception indicators). Frequency statistics will be computed for the acceptability items, as these will be measured only in the "after" survey. The software Stata 13 will be used to carry out all analyses \[[@ref31]\].

Phase IIb: Beta Testing: Focus Group
------------------------------------

### Overview

Following completion of the survey, participants were asked if they would like to participate in a focus group to allow them to give the study team more feedback about the decision aid they just viewed. If the answer was affirmative, the participant was told that he or she could be contacted within the month to make an appointment. They were also asked whether the decision aid had indicated that they were eligible for screening (based on USPSTF guidelines) and what the risk of dying due to lung cancer was as computed by the calculator.

Focus groups will be stratified by self-reported eligibility for LDCT screening. Given that one of the main goals of the tool is to increase concordance with USPSTF eligibility guidelines, it will be useful to have specific focus groups consisting of screen-(in)eligible individuals entirely. The aim is to have 4-8 individuals per focus group. Where possible, focus groups will also be stratified by sex and age, given eligibility for LDCT screening.

### Data Collection

The same steps will be followed for beta testing as those used for the focus groups conducted for alpha testing. The current version of the interview guide can be seen in [Multimedia Appendix 11](#app11){ref-type="app"}.

### Analysis

Thematic analysis will be done on the data yielded from the focus group sessions. Two study team members with qualitative analysis expertise will code the data separately and compare codes to establish the themes to be explored. A report will be given to the rest of the team, and all members will decide what changes to include for the next iteration of the decision aid.

Research Ethics
---------------

All study participants will be asked to complete consent forms. Specific consent for audiotaping of focus groups will also be sought. This study was approved by the University of Michigan Medical School Institutional Review Board on 2014 June 18 (Study ID: HUM00088232).

Results
=======

Alpha testing is completed. Beta testing is currently being carried out. As of 2014 December 7, 60 participants had completed the before-after study. We expect to have results by 2015 January 31. Qualitative data collection and analysis are expected to be completed by 2015 May 31. The current iteration of the results page with personalized risk generated by the decision aid can be seen at [Multimedia Appendix 1](#app1){ref-type="app"}.

Discussion
==========

Preliminary results from the before-after study indicate that the decision aid improves knowledge about lung cancer screening, decreases decisional conflict, and increases concordance between USPSTF recommendations and the screening option preferred by the user. Therefore, we anticipate that the decision aid will be helpful to individuals in making informed decisions about lung cancer screening.
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